载脂蛋白B基因多态性对阿托伐他汀调脂疗效的影响

摘要

目的:观察载脂蛋白B(Apo B)基因多态性对低剂量阿托伐他汀调脂疗效的影响.方法:选择高脂血症患者211例,其中67例服用阿托伐他汀10 mg,每晚1次;于治疗前及治疗开始后第4、8、12周抽血实验室检查血脂指标.采用聚合酶链式反应-限制性片段长度多态性(PCR-RFLPs)方法检测Apo B基因Xba Ⅰ酶切位点基因多态性.结果:211例高脂血症患者中,X+等位基因相对频率为0.085 3,X-等位基因相对频率为0.914 7.服用阿托伐他汀4周后,携带X+X-基因型患者的总胆固醇(TC)降低百分率较X-X-基因型患者少(14.98% vs.19.39%,P<0.05).结论:阿托伐他汀对携带X+等位基因的高脂血症患者的调脂疗效减弱.%To evaluate the effect of polymorphism in Apo B gene on the lipid-regulating efficacy of low dose of atorvastatin. METHODS: 221 patients with hyperlipidemia were enrolled, of whom, 67 were treated with oral atorvastatin (10 mg·d~(-1)) quaque nocte. The blood lipid indexes were measured before treatment and at 4, 8 and 12 weeks of treatment. The polymorphisms of Apo B gene on Xba Ⅰ locus were determined using PCR-RFLPs method. RESULTS: Of the 211 patients, the relative frequency of X+ allele and X- allele were 0.085 3 and 0.914 7, respectively. After treatment with atorvastatin for 4 weeks, the TC reduction in X + X - genotype carriers was less than in X - X - genotype carriers (14.9896 vs. 19.39%, P < 0.05) . CONCLUSION: Atorvastatin attenuates the lipid-regulating efficacy in hyperlipidemia patients carrying X+ allele.